Autobio Diagnostics Co., Ltd. (603658.SH) Latest Company News

Oct 26, 2026, 08:42 UTC
Autobio Diagnostics plans to invest RMB 99 million as a limited partner in a life-sciences fund with total subscribed capital of RMB 500 million.
Source:
- finance.sina.cn
Oct 26, 2026, 08:42 UTC
Autobio Diagnostics reported revenue of 3.24 billion yuan for the first three quarters of 2026, up 3.59% year over year, and net profit attributable to shareholders of 847 million yuan, down 1.45%.
Source:
- finance.sina.cn
Oct 26, 2026, 08:42 UTC
Autobio Diagnostics reported third-quarter 2026 revenue of 1.182 billion yuan, up 10.76% year over year, and net profit attributable to shareholders of 350 million yuan, up 21.30%.
Source:
- finance.sina.cn
Oct 12, 2026, 09:28 UTC
Antu Bio and its subsidiaries received eight medical-device registration certificates from China’s National Medical Products Administration and Henan Medical Products Administration, covering diagnostic reagents, a coagulation analyzer and quality-control products; each certificate is valid for five years.
Source:
- finance.sina.cn
Sep 30, 2026, 08:09 UTC
Autobio Diagnostics' wholly owned subsidiary Autobio Technology completed registration changes for its Medical Device Business License and Pharmaceutical Business License, with Wu Yongyin becoming legal representative and enterprise head.
Source:
- finance.sina.cn
Sep 16, 2026, 09:42 UTC
Autobio Diagnostics received a medical device registration certificate from China's National Medical Products Administration for its human immunodeficiency virus type 1 (HIV-1) nucleic acid detection kit (PCR-fluorescence probe method).
Source:
- finance.sina.cn
Sep 7, 2026, 10:03 UTC
Autobio Diagnostics and its subsidiaries received four medical device registration certificates from China's National Medical Products Administration for new diagnostic products, including a gene sequencer and three assay kits, each valid for five years.
Source:
- finance.sina.cn
Jul 8, 2026, 09:37 UTC
Autobio Diagnostics and its subsidiary Autobio Lab Instruments received two medical device registration certificates from Henan Medical Products Administration, for the AutoIntelli multi-parameter test data management software and the interleukin-12p70 detection kit.
Source:
- finance.sina.cn

603658.SH

Autobio Diagnostics plans to invest RMB 99 million as a limited partner in a life-sciences fund with total subscribed capital of RMB 500 million.

Autobio Diagnostics reported revenue of 3.24 billion yuan for the first three quarters of 2026, up 3.59% year over year, and net profit attributable to shareholders of 847 million yuan, down 1.45%.

Autobio Diagnostics reported third-quarter 2026 revenue of 1.182 billion yuan, up 10.76% year over year, and net profit attributable to shareholders of 350 million yuan, up 21.30%.

Autobio Diagnostics' wholly owned subsidiary Autobio Technology completed registration changes for its Medical Device Business License and Pharmaceutical Business License, with Wu Yongyin becoming legal representative and enterprise head.

Autobio Diagnostics received a medical device registration certificate from China's National Medical Products Administration for its human immunodeficiency virus type 1 (HIV-1) nucleic acid detection kit (PCR-fluorescence probe method).

Autobio Diagnostics and its subsidiaries received four medical device registration certificates from China's National Medical Products Administration for new diagnostic products, including a gene sequencer and three assay kits, each valid for five years.

Autobio Diagnostics and its subsidiary Autobio Lab Instruments received two medical device registration certificates from Henan Medical Products Administration, for the AutoIntelli multi-parameter test data management software and the interleukin-12p70 detection kit.